LESION OF UPPER MOTOR NEURON AND BOTULINOTHERAPY, PATHOPHYSIOLOGIC ASPECTS



Cite item

Full Text

Abstract

Movement disorders at lesions of the upper motor neuron caused by damage of brain and (or) the spinal cord and leading to the formation of spastic paresis and paralysis are one of the most common causes of disability among neurological patients. A correct understanding of the pathophysiological basis of clinical manifestations of the formation of the upper motor neuron lesion makes it possible to choose the most appropriate and successful methods of predictive correction.
Using botulinum therapy in conjunction with non-pharmacological methods of rehabilitation to reduce the activity of phasic and tonic reflexes to stretch of associated reductions, synkinesis, spastic dystonia and spasticity will improve muscle elasticity and mobility of the limbs, reduce dependence on others, eliminate pain, joint stiffness, infection, and strain soft tissues.

About the authors

Zuleikha A Zalyalova

Каzan state medical university

Email: zuleyha66@mail.ru
кафедра неврологии и реабилитации; Казанский государственный медицинский университет; Каzan state medical university

References

  1. Богданов Э.И., Тахавиева Ф.В. Симптоматическая терапия при спастичности // Неврол. вестник. - 2002. - № 3. - С. 45-50.
  2. Богданов Э.И., Зиннатуллина Э.С., Тахавиева Ф.В. Клиническая характеристика миофасциального болевого синдрома у больных с церебральными гемипарезами // Неврол. вестник. - 2002. - № 1. - С. 21-23.
  3. Залялова З.А., Krystkowiak Р., Charpentier Р. Опыт лечения препаратом ботулотоксина типа А (ботокс) во Франции // Неврол. вестник. - 2005. - Вып. 1-2. - С. 108-110.
  4. Никифоров А.С. Двигательная система: строение, функции, терминология // Журнал неврол. и психиатр. им. С.С. Корсакова. - 2004. - № 8. - С. 73-76.
  5. Парфенов В.А. Постинсультная спастичность // Лечащий врач. - 2008. - № 5. - С. 34-39.
  6. Пантелеева Е.А. Спастический парез при рассеянном склерозе: клинические, нейрофизиологические и био-химические аспекты // Неврол. журн. - 2009. - № 5. - С. 18-22.
  7. Хатькова С. Е. Опыт применения ботулотоксина типа А (препарат ксеомин) в лечении постинсультной спастич-ности // Неврол. журнал. - 2011. - № 1. - С. 50-53.
  8. Ada L., O'Dwyer N., O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study // Disabil. Rehabil. - 2006. - № 28. - Р. 891-897.
  9. Axelson H.W. Signs of muscle thixotropy during human ballistic wrist joint movements // J. Appl. Physiol. - 2005. - № 99. - P. 1922-1929.
  10. Barnes M., Schnitzler A., Medeiros L. et al. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study // Acta Neurol. Scand. - 2010. - Vol. 122(4). - P. 295-302.
  11. Bakheit A.M., Pittock S., Moore A.P. et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke // Eur. J. Neurol. - 2001. - № 8. - Р. 559-565.
  12. Benecke R., Grade S., Sassin J. Clinical safety of xeomin: a meta-analysis // Poster presentation at Distonia Europe, 2008. - Hamburg, Germany. - October 17-19.
  13. Bhakta B.B., Cozens J.A., Chamberlain M.A. et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial // J. Neurol. Neurosurg. Psychiatry. - 2000. - № 69. - P. 217-221.
  14. Bourbonnais D. Quantification of upper limb synkinesis in hemiparetic subjects // Rehabilitation R and D Progress Report. - 1995. - Vol.32. - P.118-119.
  15. Brashear A., Gordon M.F., Elovic E. et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. Botox Post-Stroke Spasticity Study Group // N. Engl. J. Med. - 2002. - № 347. - P. 395-400.
  16. Burbaud P. A., Wiart L., Dubos J.L. et al. Randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients // J. Neurol. Neurosurg. Psychiatry. - 1996. - № 61. - P. 265-269.
  17. Childers M.K., Brashear A., Jozefczyk P. et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke // Arch. Phys. Med. Rehabil. - 2004. - №. 84. - P. 1063-1069.
  18. Denny-Brown В. Historical aspects of the relation of spasticity to movement / In: Feldman R.G., Young R.R., Koella W.P., eds. Spasticity: Disordered Movement control. - Chicago: Year Book Medical Publshers, 1980. - P. 1-15.
  19. Dietz V., Trippel M., Burger W. Reflex activity and muscle in spasticity // Ann. Neurol. - 1991. - №30. - P. 767-779.
  20. Gossman M.R., Rose S.J., Sahrmann S.A. et al. Length and circumference measurement in one-joint and multijoint muscles in rabbits after immobilization // Phys. Ther. - 1986. - №. 66. - P. 516-520.
  21. Gracies J.M., Elovic E., R. Zorowitz R et al. Traditional pharmacologic treatment for spasticity part I: Local treatment / In: Brasher J., Mayer N.H., eds. Upper Motor Neuron Syndrome: Etiology, Evaluation, Management and the Role of Botulinum Toxin. - New York:WE MOVE, 2008. - P. 57-79.
  22. Graham H., Selber P. Musculoskeletal aspects of cerebral palsy // J. Bone Joint Surg. - 2003. - № 85B. - P. 157-166.
  23. Herman R., Freedman W., Meeks S.M. Physiological aspects of hemiplegic and paraplegic spasticity / In: Desmedt J.E., ed. New Developments in Electromyography and Clinical Neurophysiology, Basel: Karger, 1973. - P. 579-588.
  24. Herman R. The myotatic reflex. Clinico-physiological aspects of spasticity and contracture // Brain. - 1970. - №. 93. - P. 273-312.
  25. Hesse S., Reiter F., Konrad M. et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial // Clin. Rehabil. - 1998. - №. 12. - P. 381-388.
  26. Jankowska E., Lackberg Z.S., Dyrehag L.E. Effects of monoamines on transmissiom from group II muscle afferents in sacral segments in the cat // Eur. J. Neurosci. - 1994. - № 6. - P. 1058-1061.
  27. Kanovsky P., Sassin I., Comes G. et al. NT 201 Study Group (Olomouc, Czech Republic) // J. Rehabil. Med. - 2011. - Vol.43. - P.486-492.
  28. Keenan M.A.E., Mehta S. Neuro-orthopedic management of shoulder deformity and dysfunction in brain-injured patients // J. Head Trauma Rehabil. - 2004. - № 19. - P. 143-154.
  29. Mayer N.H., Herman R.M. Phenomenology of muscle overactivity in the upper motor neuron syndrome // Eura Medicophys. - 2004. - № 40. - P. 85-110.
  30. Mayer N.H., Esquenazi A., Childers M.K. Common patterns of clinical motor dysfunction / In: Mayer N.H., Simp-son D.M., eds. Spasticity: Etiology, Evaluation. Management and the role of Botulinum Toxin. - New York: WE MOVE, 2002. - P. 16-26.
  31. Mayer N.H., Esquenazi A. Upper Limb Skin and Musculoskeletal consequences of the upper motor neuron syndrome / In: Jankovic J., eds. Botulinum Toxin Therapeutic Clinic Practice and Science: Houston, 2009. - P. 131-146.
  32. McDaid P.K., Keenan MAE. Management of upper extremity dysfunction following stroke and brain injury / In: Chapman M., ed. Chapman's Orthopaedic Surgery. - Philadelphia: Lippincott Wiliams & Wilkins, 2001. - P. 1809-1854.
  33. Meythaler J.M., Guin-Renfroe S., Brunner R.C. et al. Intrathecal baclofen for spastic hypertonia from stroke // Stroke. - 2001. - № 32. - P. 2099-2109.
  34. Pittock S.J., Moore A.H., Hardiman O. et al. A double-blind randomized placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke // Cerebrovasc. Dis. - 2003. - № 15. - P. 289-300.
  35. Pohl M., Mehмrholz J., Rockstroh G. et al. Contractures and involuntary muscle overactivity in severe brain injury // Brain Inj. - 2007. - № 21. - P. 421-432.
  36. Sheean G. Neurophysiology of spasticity / In: Barnes MP, Johnson GR, eds. Upper Motor Neurone Syndrome and Spasticity, Clinical Management and Neurophysiology. - Cambridge, UK: Cambridge University Press, 2001. - P. 12-78.
  37. Sheean G. The pathophysiology of spasticity // Eur. J. Neurol. - 2002. - № 9. - P. 3-9.
  38. Simpson D.M., Alexander D.N., O'Brien C.F. et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial // Neurology. - 1996. - № 46. - P. 1306-1310.
  39. Smith C., Birnbaum G. et al. US Tizanidine Study Group. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial // Neurology. - 1994. - № 44. - P. 34-44.
  40. Smith S.J., Ellis E., White S. et al. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury // Clin. Rehabil. - 2000. - № 14. - P. 5-13.
  41. Suputtitada A., Suwanwela N.C. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity // Disabil. Rehabil. - 2005. - № 27. - P. 176-184.
  42. Vattanasilp W., Ada L., Crosbie J. Contribution ofthixotropy, spasticity, and contracture to ankle stiffness after stroke // J. Neurol. Nurosurg. Psychiatry. - 2006 - № 69. - P. 34-39.
  43. Thilmann A.F., Fellows S.I., Ross H.F. Biomechanical changes at the ankle joint after stroke // J. Neurol. Neurosurg. Psychiatry. - 1991. - № 54. - P. 134-139.
  44. Walshe FMR. On certain tonic or postural reflexes in hemiplegia, with special reference to the so-called "associated movements" // Brain. -1923. - № 46. - P. 1-37.
  45. Witzmann F.A., Kim D.H., Fitts R.H. Hindlimb immobilization: length-tension and contractile properties of skeletal muscle // J. Applied Physiol. - 1982. - № 53. - P. 335-345.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Zalyalova Z.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies